舌痛症患者に対するラフチジンとクロチアゼパムの臨床効果の比較検討

概要

論文の詳細を見る
Lafutidine is a new H2-receptor antagonist that not only has a strong inhibitory effect on gastric secre tionbut also augments the gastric mucosa protection factor and dilate arterioles in the gastric submucosa and enhances gastric mucosal blood flow via capusaicin sensitiveafferent neurons. We suggest that lafutidine may also be effective in the tongue for patients diagnosed with glossodynia. We compared the clinical effect of lafutidine with clotiazepam. This treatment was performed in 54 glossodynia patients; lafutidine was administered at a dose of 10 mg twice a day for 29 patients, and clotiazepam was administered at a dose of 5 mg three times a day for 25 patients for 8 weeks. The improvement rate of pain (improved and better) on lafutidine was 69.0%(20/29 cases) after 2 weeks, and 84.0%(27/29 cases) after 8 weeks. The pain on VAS was 46.8 mm on average before admini stration, and 10.2 mm on average after 8 weeks. On the other hand, clotiazepam showed almost no im provement. In conclusion, lafutidine exhibited good clinical efficacy and safety and utility in the treatment of glossodynia.
特定非営利活動法人日本口腔科学会の論文
2003-07-10